/

GRCE

Grace Therapeutics, Inc.Open

1.92−0.07 −3.52%USD

NasdaqCM · as of Oct 14, 14:28 ET · 15m delay

Open

1.96

Prev close

1.99

Day range

1.912.01

52-week range

1.795.18

Volume

82.85K0.50×

Mkt cap

40.39M

P/E ttm

—

Fwd P/E

-4.28

EPS ttm

-1.17

Div yield

0.00%

Earnings

—

From 52w high

−62.93%

Price Chart

Yahoo Finance · delayed

GRCEOct 14, 2026O 1.96H 2.01L 1.91C 1.92−0.07 (−3.52%)Vol 82.85K

SMA 502.12
SMA 2002.92

1Y change −35.79% since Oct 13, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

GRCE Grace Therapeutics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −8.57%
1 month: −16.16%
3 months: −20.99%
6 months: −55.96%
Year to date: −44.51%
1 year: −36.21%

Valuation & ownership

Market cap: 40.39M
Enterprise value: 28.11M
P/E (ttm): —
Forward P/E: -4.28
PEG ratio: —
Price / book: 0.65
Price / sales (ttm): —
EV / EBITDA: -2.71
EPS (ttm): -1.17
EPS (forward): -0.4481
Beta (5y monthly): 0.33
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 21.04M
Float: 13.47M
Short % of float: 9.45%
Short ratio (days): 11.82
Held by insiders: 18.68%
Held by institutions: 31.51%
Avg volume (3m): 165.45K
50-day average: 2.13
200-day average: 2.93
52-week change: −36.21%
S&P 500 52-week: +17.00%

Technicals (daily)

RSI (14): 33.7
vs 50-day SMA: −9.65%
vs 200-day SMA: −34.22%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 4.62%
Realised vol (20d, ann.): 32.3%
From 52-week high: −62.93%
From 52-week low: +7.26%

ANR

Analyst Consensus

2 analysts

Consensus

—

Mean target

5.85

+204.89% implied

Low 3.89Median 5.85High 7.81

Recommendation trend

Now2 / 0 / 0
1m ago2 / 0 / 0

Buy / hold / sell counts

DES

About Grace Therapeutics, Inc.

Yahoo Finance profile

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to enhance neurological symptoms of Ataxia-Telangiectasia (A-T); and GTX-101, a topical bio adhesive film-forming bupivacaine spray for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Sector: Healthcare
Industry: Biotechnology
Employees: 5
Headquarters: Princeton, NJ, United States
Website: gracetx.com
Officers: Mr. Prashant Kohli CEO & Director
Mr. Amresh Kumar Ph.D. VP of Program Management
Ms. Carrie D'Andrea Consultant
Mr. Robert J. DelAversano CPA VP of Finance and Principal Financial & Accounting Officer

SEAS

Seasonality · GRCE

2012–2026 · monthly returns

Strongest month Jul +14.54%Weakest month Aug −15.37%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	4.9	18.2	7.9	-51.6	14.7	-11.7	-8.4	2.4	0.9	-10.7			−44.5%
2025	-11.8	-8.2	-24.8	14.5	6.1	7.2	-2.7	4.8	-1.7	6.0	0.6	8.8	−7.5%
2024	-14.2	34.7	2.7	-19.0	-1.8	7.0	-7.5	-3.0	14.5	6.7	5.0	11.3	+29.4%
2023	42.0	-28.2	-9.8	-2.2	20.0	-1.9	-18.9	-20.2	35.0	-15.1	-8.1	33.2	−3.7%
2022	-8.7	-2.6	8.9	-13.9	-6.7	-12.2	-3.5	-2.4	-28.4	-1.7	-26.3	19.0	−60.3%
2021	97.0	10.8	-16.7	-18.3	2.0	12.0	-17.9	-27.4	-25.1	-16.5	-19.2	-6.7	−52.3%
2020	-70.2	-41.1	-11.6	60.5	3.3	-25.4	61.7	-68.4	-16.7	-5.0	52.6	13.8	−86.5%
2019	28.9	0.9	-5.6	-14.7	3.4	26.7	111.4	-22.4	1.1	-2.6	8.2	23.1	+195.2%
2018	20.2	-11.5	2.0	-24.5	-10.4	-17.4	3.5	-5.1	130.4	-22.5	-27.0	13.7	−11.7%
2017	1.6	-1.6	8.8	-5.9	0.8	2.3	0.0	-3.0	10.9	-9.9	30.5	-43.7	−24.8%
2016	-38.8	-3.8	1.3	-7.2	6.4	-8.0	12.3	-14.2	34.6	-25.1	4.5	-10.7	−51.0%
2015	-8.0	19.6	-12.7	-16.7	-17.5	-3.0	12.5	0.0	-25.0	-16.3	1.8	10.9	−49.0%
2014	1.6	0.0	-9.4	-12.2	-14.9	18.6	-2.0	-6.0	-18.1	-29.9	-22.2	19.0	−60.0%
2013	20.9	-12.3	-6.6	10.8	7.6	11.4	42.4	-38.0	-5.2	-19.4	-35.1	0.8	−41.9%
2012			27.3	8.6	3.1	-12.8	12.2	-10.0	-2.9	17.9	11.4	-18.6	+30.3%

INSD

Insider Activity · GRCE

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Oct 11, 2026	Opaleye Management, Inc.Beneficial Owner of more than 10% of a Class of Security	Purchase at price 2.02 - 2.04 per share.	14.6K	$29.68K
Oct 4, 2026	Opaleye Management, Inc.Beneficial Owner of more than 10% of a Class of Security	Purchase at price 2.04 - 2.07 per share.	60.5K	$123.82K
Sep 28, 2026	Opaleye Management, Inc.Beneficial Owner of more than 10% of a Class of Security	Purchase at price 2.09 per share.	7.8K	$16.40K
Sep 22, 2026	Opaleye Management, Inc.Beneficial Owner of more than 10% of a Class of Security	Purchase at price 2.10 per share.	15.1K	$31.69K
Sep 22, 2026	Opaleye Management, Inc.Beneficial Owner of more than 10% of a Class of Security	Purchase at price 2.10 per share.	15.1K	$31.69K
Sep 8, 2026	Opaleye Management, Inc.Beneficial Owner of more than 10% of a Class of Security	Purchase at price 2.09 - 2.10 per share.	15.2K	$31.90K
Sep 8, 2026	Kohli PrashantChief Executive Officer	Purchase at price 2.14 per share.	100K	$214.00K
Aug 13, 2026	Opaleye Management, Inc.Beneficial Owner of more than 10% of a Class of Security	Purchase at price 2.09 per share.	11.6K	$24.21K

GRCE

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

GRCE

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Grace Therapeutics, Inc.

Seasonality · GRCE

Insider Activity · GRCE

Congress Trades · GRCE

Investors Holding GRCE

Investors Holding GRCE

Congress Trades · GRCE

Insider Activity · GRCE

Seasonality · GRCE

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Grace Therapeutics, Inc.

Financial Snapshot

Earnings & Dividends

News